Schering-Plough considering Bristol-Myers Squibb buyout

Schering-Plough is seriously considering approaching Bristol-Myers Squibb about a possible merger, the New Jersey newspaper, The Star–Ledger, reported on its Web site. The article cited “three people with direct knowledge of Schering-Plough’s deliberations,” as its source. “The concept would be the management of Schering-Plough would be the management of the joint-company,” one of the people involved with the discussions said. “One of the intangibles in this is (Schering-Plough CEO, Fred Hassan) himself.” The people with knowledge of Schering-Plough’s strategy said such a merger plan has been discussed for months. However, Schering-Plough has yet to approach Bristol-Myers with a proposal. Schering-Plough’s strategy would be to orchestrate a “reverse merger,” under which Bristol-Myers would acquire the smaller company for stock, the Star-Ledger story said. “It would be a merger of equals,” one of the people involved in the discussions said. Analysts noted that a stumbling block to such a deal could be in Schering-Plough’s joint venture with Merck to manufacture and market the cholesterol drugs Vytorin and Zetia. The drugs had combined sales of $2.4 billion last year. The agreement gives Merck the right to buy out Schering-Plough’s stake if it merges with a larger drug maker. However, Schering-Plough would keep its share of the Vytorin franchise in a “merger of equals” that gives Schering-Plough’s shareholders 40% of the shares in the combined company, according to Securities and Exchange Commission filings.  Some analysts remained skeptical about the idea of a merger between the two companies. “In our assessment, Schering-Plough could be launching a trial balloon, to test the response of their shareholders to such a merger,” said Barbara Ryan, large caps pharmaceuticals analyst at Deutsche Bank Securities, in a published report. Steve Scala, an analyst at SG Cowen, said the speculation is nothing more than hot air. “I do not think that Bristol-Myers is an acquisition target right now given the uncertainty over Plavix,” he told Reuters. “We ultimately think Bristol-Myers will win the Plavix litigation but that doesn't affect the value of a deal now.”

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions